Congenital nephrogenic diabetes insipidus treated with acetazolamide.
acetazolamide
congenital
diabetes insipidus
nephrogenic
Journal
Nephrology (Carlton, Vic.)
ISSN: 1440-1797
Titre abrégé: Nephrology (Carlton)
Pays: Australia
ID NLM: 9615568
Informations de publication
Date de publication:
07 Mar 2024
07 Mar 2024
Historique:
revised:
27
02
2024
received:
08
11
2023
accepted:
01
03
2024
medline:
7
3
2024
pubmed:
7
3
2024
entrez:
7
3
2024
Statut:
aheadofprint
Résumé
Congenital nephrogenic diabetes insipidus (CNDI) is a rare disorder. The condition is characterised by an inability of distal nephron segments to respond to normal or raised concentrations of serum antidiuretic hormone. In this report, we describe the case of a 13-year-old male known with CNDI who experienced a pedestrian vehicle accident leading to coma following a head injury. Intra-operatively, severe hypernatraemia and polyuria were observed. Following an inadequate response to conventional therapy, acetazolamide was prescribed resulting in an immediate response to therapy. To the best of our knowledge, acetazolamide has not been previously documented as a therapeutic option for CNDI. Additional research is necessary before considering the recommendation of acetazolamide for cases of NDI that do not respond adequately to conventional treatments.
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Authors. Nephrology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Nephrology.
Références
Arthus M-F, Lonergan M, Crumley JM, et al. Report of 33 novel AVPR2 mutations and analysis of 117 families with X-linked nephrogenic diabetes insipidus. J Am Soc Nephrol. 2000;11:1044-1054.
Duicu C, Pitea AM, Săsăran OM, Cozea I, Man L, Bănescu C. Nephrogenic diabetes insipidus in children. Exp Ther Med. 2021;22:1-6.
Milano S, Carmosino M, Gerbino A, Svelto M, Procino G. Hereditary nephrogenic diabetes insipidus: pathophysiology and possible treatment. An Update. Int J Mol Sci. 2017;18:2385.
Halperin M, Kamel K. Hypokalemia. Fluid, Electrolyte, and Acid-Base Physiology: a Problem-Based Approach. Saunders. Elsevier; 2017.
Asim M, Alkadi MM, Asim H, Ghaffar A. Dehydration and volume depletion: how to handle the misconceptions. World J Nephrol. 2019;8:23-32.
Chothia M-Y, George K, Sheik M, Davids MR. Hypodipsic-hypernatremia syndrome in an adult with polycythemia: a case report. J Med Case Reports. 2018;12:1-6.
Bankir L, Bichet DG, Morgenthaler NG. Vasopressin: physiology, assessment and osmosensation. J Intern Med. 2017;282:284-297.
Bendz H, Aurell M. Drug-induced diabetes insipidus: incidence, prevention and management. Drug Saf. 1999;21:449-456.
Stasior D, Kikeri D, Duel B, Seifter J. Nephrogenic diabetes insipidus responsive to indomethacin plus dDAVP. N Engl J Med. 1991;324:850-851.
D'Alessandri-Silva C, Carpenter M, Ayoob R, et al. Diagnosis, treatment, and outcomes in children with congenital nephrogenic diabetes insipidus: a pediatric nephrology research consortium study. Front Pediatr. 2020;7:550.
Allen HM, Jackson RL, Winchester MD, Deck LV, Allon M. Indomethacin in the treatment of lithium-induced nephrogenic diabetes insipidus. Arch Intern Med. 1989;149:1123-1126.
de Groot T, Sinke AP, Kortenoeven ML, et al. Acetazolamide attenuates lithium-induced nephrogenic diabetes insipidus. J Am Soc Nephrol. 2016;27:2082-2091.
Kassamali R, Sica DA. Acetazolamide: a forgotten diuretic agent. Cardiol Rev. 2011;19:276-278.
Taki K, Oogushi K, Hirahara K, Gai X, Nagashima F, Tozuka K. Preferential acetazolamide-induced vasodilation based on vessel size and organ: confirmation of peripheral vasodilation with use of colored microspheres. Angiology. 2001;52:483-488.
Gordon CE, Vantzelfde S, Francis JM. Acetazolamide in lithium-induced nephrogenic diabetes insipidus. N Engl J Med. 2016;375:2008-2009.